Insider Selling: Trupanion, Inc. (NASDAQ:TRUP) CFO Sells 1,373 Shares of Stock

Trupanion, Inc. (NASDAQ:TRUP) CFO Fawwad Qureshi sold 1,373 shares of the stock in a transaction on Wednesday, February 26th. The stock was sold at an average price of $34.22, for a total value of $46,984.06. Following the completion of the sale, the chief financial officer now owns 2,416 shares of the company’s stock, valued at $82,675.52. The trade was a 36.24 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Fawwad Qureshi also recently made the following trade(s):

• On Friday, November 29th, Fawwad Qureshi sold 9,867 shares of Trupanion stock. The shares were sold at an average price of $53.08, for a total value of $523,740.36.

Trupanion Stock Up 2.8 %

Shares of NASDAQ TRUP opened at $34.54 on Friday. The company has a 50-day moving average of $45.87 and a 200 day moving average of $47.79. Trupanion, Inc. has a 12-month low of $19.69 and a 12-month high of $57.90. The company has a current ratio of 1.71, a quick ratio of 1.66 and a debt-to-equity ratio of 0.39. The stock has a market cap of $1.46 billion, a PE ratio of -150.17, a P/E/G ratio of 6.02 and a beta of 1.60.

Trupanion (NASDAQ:TRUP) last posted its quarterly earnings results on Wednesday, February 19th. The financial services provider reported $0.04 earnings per share for the quarter, missing the consensus estimate of $0.06 by ($0.02). Trupanion had a negative net margin of 0.75% and a negative return on equity of 3.08%. The firm had revenue of $337.31 million during the quarter, compared to analysts’ expectations of $335.41 million. As a group, sell-side analysts predict that Trupanion, Inc. will post 0.13 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently commented on TRUP. Piper Sandler dropped their price target on Trupanion from $57.00 to $52.00 and set an “overweight” rating for the company in a research report on Thursday, February 20th. Stifel Nicolaus decreased their target price on shares of Trupanion from $44.00 to $41.00 and set a “hold” rating for the company in a research report on Thursday, February 20th. Two analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Trupanion presently has a consensus rating of “Moderate Buy” and a consensus target price of $46.60.

Institutional Trading of Trupanion

Hedge funds have recently made changes to their positions in the company. FMR LLC grew its stake in shares of Trupanion by 55,963.7% in the 3rd quarter. FMR LLC now owns 1,172,293 shares of the financial services provider’s stock valued at $49,213,000 after buying an additional 1,170,202 shares during the period. Barclays PLC boosted its position in shares of Trupanion by 259.2% during the 3rd quarter. Barclays PLC now owns 65,498 shares of the financial services provider’s stock worth $2,750,000 after purchasing an additional 47,262 shares during the period. Centiva Capital LP purchased a new position in shares of Trupanion during the 3rd quarter worth approximately $595,000. FORA Capital LLC purchased a new position in shares of Trupanion during the 3rd quarter worth approximately $540,000. Finally, Blueshift Asset Management LLC boosted its position in shares of Trupanion by 215.8% during the 3rd quarter. Blueshift Asset Management LLC now owns 37,230 shares of the financial services provider’s stock worth $1,563,000 after purchasing an additional 25,440 shares during the period.

Trupanion Company Profile

Trupanion, Inc, together with its subsidiaries, provides medical insurance for cats and dogs on a monthly subscription basis in the United States, Canada, Continental Europe, and Australia. The company operates in two segments, Subscription Business and Other Business. It serves pet owners and veterinarians.